STOCK TITAN

Coya Therapeutics, Inc. - COYA STOCK NEWS

Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.

Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company advancing novel therapies that modulate regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic disorders. This page serves as the definitive source for official updates and analysis on COYA's progress in developing innovative immunology solutions.

Investors and researchers will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations. Our curated news collection includes verified information on therapy pipeline advancements, intellectual property updates, and financial disclosures essential for evaluating this innovative biotech company.

Key content focuses on COYA's multi-modality Treg platform developments, partnership announcements with research institutions, and progress toward addressing high-need conditions like ALS and Alzheimer's disease. All materials maintain journalistic rigor while avoiding speculative commentary.

Bookmark this page for structured access to COYA's latest scientific advancements and corporate developments. Check regularly for updates on this pioneering company's efforts to translate Treg research into transformative therapies.

Rhea-AI Summary

Coya Therapeutics has completed a Phase 2 study on low-dose Interleukin-2 (LD IL-2) for mild-to-moderate Alzheimer's disease (AD). The double-blind, placebo-controlled study involved 38 patients over 30 weeks and was funded by the Gates Foundation and Alzheimer’s Association. The study aims to assess the safety, tolerability, and biological activity of LD IL-2. Preliminary data showed significant improvements in cognitive function and Treg cell activity in an earlier open-label study. Topline results are expected in summer 2024. The study was led by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
-
Rhea-AI Summary

Coya Therapeutics has announced a $5 million investment from the Alzheimer's Drug Discovery Foundation (ADDF) to support the development of COYA 302 for Frontotemporal Dementia (FTD). The investment involves the purchase of 603,136 shares at $8.29 per share. COYA 302, a combination drug, aims to suppress neuroinflammation by targeting multiple inflammatory pathways. This move aligns with ADDF's strategy of combination therapies for treating complex neurodegenerative diseases.

The funds will help advance COYA 302 into a Phase 2 trial for FTD. The ADDF's support reinforces the potential of combination therapies in combating diseases like Alzheimer's and FTD, which lack effective treatment options currently.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
none
-
Rhea-AI Summary

Coya Therapeutics, Inc. (Nasdaq: COYA) has expanded its clinical pipeline with COYA 302 for neurodegenerative diseases such as ALS, Parkinson's, FTD, and AD. The company announced successful meetings with the FDA, expanded patents, and presented data on immune system contributions. Coya's CEO highlighted the potential of COYA 302 in treating complex immune pathways and neurodegenerative diseases. Financially, Coya had $36.0 million in cash and cash equivalents as of March 31, 2024, with increased R&D and administrative expenses leading to a net loss of $5.1 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
Rhea-AI Summary
Coya Therapeutics presents updated ALS biomarker data at the 2nd Annual Johnson Center Symposium. Serum 4-Hydroxynonenal levels show a correlation with ALS progression and survival, with higher levels indicating faster disease progression. The data suggests that 4-HNE could be a promising biomarker in ALS and an independent monitor of clinical status for the upcoming COYA 302 Ph. 2 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
none
-
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) will have its CEO and Chief Business Development Officer participate in the Mizuho Neuroscience Summit on May 20-21, showcasing their biologics enhancing Treg function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences
-
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces participation in the 3rd Annual ALS Drug Development Summit by President and Chief Medical Officer Dr. Fred Grossman. Dr. Grossman will lead a workshop on combination therapy approaches and present COYA 302, a dual mechanism biologic immunotherapy for ALS treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
conferences
Rhea-AI Summary
Coya Therapeutics, Inc. (COYA) presents updated ALS biomarker data showing a high correlation between 4-HNE levels and ALS disease progression. The Company plans to validate 4-HNE as a new potential biomarker for ALS and include it in a planned Phase 2 trial with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
management conferences
-
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces positive clinical trial results for its biologics in treating neurodegenerative diseases, along with key corporate developments and financial results for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. announces that Dr. Stanley Appel and Dr. Fred Grossman will participate in a discussion hosted by BTIG Analyst Tom Shrader. They will talk about the role of regulatory T cells in treating neurodegenerative diseases, ALS survival data, and Coya's lead drug candidate COYA 302 for ALS, Parkinson's, Frontotemporal, and Alzheimer's diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
conferences
Rhea-AI Summary
4-Hydroxynonenal (4-HNE) levels strongly correlate with the rate of Amyotrophic Lateral Sclerosis (ALS) disease progression and patient survival, making it a potential biomarker for tracking treatment efficacy. Coya Therapeutics, Inc. (Nasdaq: COYA) presents promising biomarker data at the Society of Neuroimmune Pharmacology Conference, indicating the importance of 4-HNE in ALS pathophysiology and patient outcomes. The company plans to validate 4-HNE as a new biomarker for predicting disease progression and survival in ALS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
none
Coya Therapeutics, Inc.

Nasdaq:COYA

COYA Rankings

COYA Stock Data

87.97M
14.66M
7.03%
26.72%
1.63%
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON